New purification and filling facility illustrates Grifols’ commitment to growth in Clayton
Growth will make the Grifols Clayton site one of the largest plasma manufacturing plants in the world
Clayton – Johnston County’s largest private employer continues it multi-million dollar expansion. The global need for plasma-derived medicines is growing, and so is Grifols, Johnston County’s largest private employer.
As part of its $210 million investment to expand facilities at its Clayton site, Grifols broke ground Tuesday on a new $120 million purification and filling facility to be used primarily for immunoglobulin and Factor VIII products.
The three-story, 150,000 ft purification and filling facility, expected to begin operation in 2022, will play a key role in Grifols’ manufacturing process.
In addition to purification and filling, the facility will also have dedicated areas for receiving raw materials and glassware and housing equipment.
“The new purification and filling facility is crucial to Grifols’ expansion plans at the Clayton site,” said Juan Antonio Garcia Diaz, President of Grifols Therapeutics LLC. “We strive to meet the needs and have the trust of patients around the world, so investing in a facility that will help ensure the quality and safety of our products is a top priority.”
In addition, Grifols is in the process of building a new plasma fractionation facility at the Clayton site. The facility will have a fractionation capacity of 6 million liters per year and is expected to open in 2021. The opening of this facility will make Grifols’ Clayton site one of the largest plasma manufacturing plants in the world.
Between 2011 and 2017 Grifols has invested approximately $760 million in Clayton. With the new facility and a new administrative building, Grifols is set to invest another $320 million between 2017 and 2022.
Gov. Roy Cooper will be visiting Grifols in Clayton on Thursday.
In December 2017, Grifols tripled the size of its Clayton site with the purchase of 467 acres, which will be used for future site expansion.
In July 2017, Grifols opened a 112,000 ft office building for more than 400 employees.
About Grifols
Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.
Grifols’ three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and services that are available in more than 100 countries.
With a network of 190 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.
Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries.
In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).
